The outlook of companies tied to Viagra's legacy presents a complex investment scenario . While the initial surge generated substantial profits , generic alternatives have significantly eroded market share . Investing in related pharmaceutical businesses now requires a discerning assessment of proprietary rights , evolving healthcare shifts , and t